FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:215-217 July 19, 2001 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

It is currently estimated that between 2.7 million and 4.0 million persons in the United States have chronic hepatitis C virus (HCV) infection.¹ Many of these persons have potentially progressive disease. Studies suggest that mortality and health care costs from complications of chronic hepatitis C and cirrhosis, such as hepatocellular carcinoma and liver failure, will increase dramatically over the next 10 to 20 years.^2,3 Several reports indicate that this increase has already begun to occur.^4,5 Thus, the development of more effective interferon-based treatments is particularly encouraging. A standard regimen of interferon and ribavirin results in sustained eradication of HCV in . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Rifai, M. A., Rosenstein, D. L. (2005). Hepatitis C and Psychiatry. Focus 3: 194-202 [Abstract] [Full Text]